[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100294752":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":59,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":74,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hemophagocytosis",null,"Subjects should fulfill the following criteria\n\n1. Subjects should have at least one of the following problems\n\n   1. Presence of hemophagocytosis in tissue or bone marrow\n   2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria\n2. Age \\> 18 years\n3. Written informed consents\n\nSubjects receive steroids and etoposide",[13,14],"Drug: Steroids","Drug: Etoposide",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Steroids","High dose dexamethasone 20 mg PO or IV",[9],[22],"Dexamethasone",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Etoposide","Etoposide 150mg\u002FBSA",[9],[28],{"name":29,"affiliation":5,"role":30},"Seok Jin Kim, MD, PhD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","+82234101766","kstwoh@skku.edu",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},"Silvia Park, MD, PhD","+82234103459","silvia.park@samsung.com",[41],{"facility":5,"status":42,"city":43,"state":10,"zip":44,"country":45,"countryCode":10,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Seoul","135-710","South Korea",{"type":47,"coordinates":48},"Point",[49,50],126.9784,37.566,{"lat":50,"lon":49},[53,55,56],{"name":29,"role":33,"phone":54,"phoneExt":10,"email":35},"82-2-3410-1766",{"name":29,"role":30,"phone":10,"phoneExt":10,"email":10},{"name":57,"role":58,"phone":10,"phoneExt":10,"email":10},"Won Seog Kim, MD, PhD","SUB_INVESTIGATOR",{"type":60,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100294752","prospective-cohort-for-adult-hemophagocytosis-100294752",false,"NCT03117010","Prospective Cohort for Adult Hemophagocytosis","A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like Syndrome","Inclusion Criteria:\n\n* Subjects should fulfill the following criteria\n\n  1. Subjects should have at least one of the following problems\n\n     1. Presence of hemophagocytosis in tissue or bone marrow\n     2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria\n  2. Age \\> 18 years\n  3. Written informed consents\n\n     Exclusion Criteria:\n* Subjects cannot satisfy the inclusion criteria","ALL","18 Years","80 Years",{"count":72,"type":73},81,"ESTIMATED","3 Years","OBSERVATIONAL","This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.",[78],"Hemophagocytic Lymphohistiocytoses",[80],"Hemophagocytic lymphohistiocytosis","2026-04-23",{"date":83,"type":84},"2026-04-24","ACTUAL",{"date":86,"type":84},"2017-01-01",{"date":88,"type":73},"2028-12-31",{"name":5,"class":6},1]